FDA gives once-yearly zoledronic acid injection expanded use.

A new dosage form of once per month is now available for the osteoporosis drug Actonel.

National Osteoporosis Foundation releases new clinician?s guide.

FDA issues warning for bisphosphonates.

AHRQ report examines use of osteoporosis drugs

New selective estrogen receptor modulators (SERMs), new combinaton drugs, and more convenient dosing forms are under development for osteoporosis.

Osteoporosis occurs most commonly in postmenopausal women, and the incidence increases with age. This concern has prompted the North American Menopause Society (NAMS) to issue a new evidence-based position statement on the role of calcium in peri- and postmenopausal women.

New molecular entities on the horizon for the treatment of osteoporosis face a tough row to hoe in their quest for approval from the Food & Drug Administration. That was the subject of a presentation at the 2006 Annual Meeting of the American College of Clinical Pharmacy (ACCP), held in October in St. Louis.

Although jaw osteonecrosis is a rare complication of bisphosphonate therapy, the sheer numbers of bisphonphonate Rxs filled annually suggest this rare side effect may affect thousands of patients. Bisphosphonates are indicated for treating hypercalcemia of malignancy, multiple myeloma, bone metastases of solid tumors and Paget's disease, and for the treatment and prevention of osteoporosis.